Alterations identified on the F1H panel included those among CDKN2A (p16/Ink4) and CDKN2B, which are well established in solid malignancies, including lung, breast, pancreatic, melanoma, and a variety of head and neck carcinomas, as well as in pre-B cell acute lymphoblastic leukemia (ALL) [29–31]. Here, CDKN2A is linked to melanoma.